Abstract 61P
Background
Natural killer (NK) cells may be particularly suited to cancer therapy. However, the heterogeneity of NK cell populations poses challenges in isolating highly functional subpopulations for therapeutic applications. This study presents a novel microfluidic platform that can select NK cells with enhanced avidity, aiming to improve the precision and efficacy of NK cell-based immunotherapies.
Methods
We used a microfluidics device that uses fluid shear stress to sort and isolate and sort NK cells based on their avidities to the target cells. Briefly, we sterilized our chip and coated it with fibronectin overnight and cultured lung cancer (A549) and ovarian cancer (SKOV3) cells for 24 hours until they achieved a monolayer. We then introduced NK cells on top of the monolayer and left these two types of cells to interact under static condition for 10 minutes. Using syringe pump, we applied fluid flow to induce shear ranging from 0.5Pa to 19.8 Pa in order to isolate the NK cells after each flow. To explore if avidity correlated with cytotoxicity, we cultured monolayer of A549 on our chip then introduced two types of NK cells: treated NK cells (adNK) and NK cells isolated from peripheral blood (cbNK). We followed the same protocol as described above to determine the NK cell type with high avidity.
Results
Our results show that at least 4.5 % and 4% cbNK cells remained attached to SKOV3 cells and A549 respectively after exposure to shear as high as 19.8 Pa. This avidity profile was different for adNK cells on A549. 30% of and NK cells remained attached to A549 cells after 19.8 Pa shear. This result also matched the cytotoxicity profile of adNK cells compared to that of cbNk cells for A549 cells.
Conclusions
In this study we used a novel method to sort and isolate NK cells based on their avidity to its target cancer cells. Although this device has been used to isolate and sort T cell population before, to our knowledge, for the first time we showed that NK cells can be isolated using their avidity to target cells. In addition, the higher avidity adNk cell aligned with its high cytotoxicity suggesting that selecting NK cells based on avidity may lead to selection of potent NK cells.
Legal entity responsible for the study
Imperial College London.
Funding
Imperial College London, Department of Bioengineering Imperial College London, Department of Life Sciences.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial
Presenter: HAIBIN ZHANG
Session: Poster Display
91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
Presenter: Wei zhang
Session: Poster Display
92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study
Presenter: hongjie Cai
Session: Poster Display
93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.
Presenter: Margherita Rimini
Session: Poster Display
94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma
Presenter: Qin-qin Liu
Session: Poster Display
95P - A single-arm, multicenter phase ? trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Junsheng Wang
Session: Poster Display
97P - ICI for patients with MSS metastatic colorectal cancer
Presenter: Zayana Sangadzhieva
Session: Poster Display
Resources:
Abstract
99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
Presenter: Hongnan Mo
Session: Poster Display
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display